FerroptoCure Singled out for Success By CIC in 2024 Review

From: https://cic.com/blog/one-year-later-2023-global-startup-acceleration-program-gsap/

FerroptoCure is determined to develop an anticancer agent that targets the ferroptosis regulatory mechanism – a mechanism for regulating cellular death that is present in all types of cancer. 2024 has been a landmark year for FerroptoCure as they racked up awards and exhibited at showcases. They have been selected to participate in multiple acceleration programs including LINK-J UNIKORN, Aichi Deeptech Launchpad and GSAP 2024 (Deep Tech). Having started Phase 1 trials in Japan, FerroptoCure is now preparing to conduct a clinical trial in the USA, and looks forward to opportunities for collaboration with pharma and fundraising.